The research team turned to spatial transcriptomics, a technology that measures gene expression across intact tissue sections while preserving the physical coordinates of every measurement. Unlike single-cell RNA sequencing, which dissociates tissue and loses positional information, spatial transcriptomics allows researchers to ask not only which genes are active, but where. The investigators applied this approach to tumor samples containing TLS and used a computational framework called EcoTyper to infer cell states — transcriptionally coherent subpopulations within broader cell lineages — directly from the spatial data. In total, they identified 71 distinct cell states spanning all of the major immune lineages present in the tumor microenvironment, from B cells and T cells to dendritic cells and neutrophils.

This cell state-level resolution proved to be the study’s decisive methodological choice. When the researchers examined how each inferred state was distributed along a gradient running from the geometric core of a TLS to its surrounding periphery, they found that cells belonging to the same lineage could behave in dramatically different ways. Some lineages contained states that were enriched within the TLS and others that were depleted there, meaning that a coarse analysis lumping all cells of a lineage together would have averaged away the very patterns the researchers were seeking. Core-periphery organization, the authors conclude, is in an important sense invisible at the cell type level and only emerges at the cell state level.

Among the most notable discoveries were two TLS-enriched CD4 T cell states with clearly distinct marker gene programs. Although both belonged to the helper T cell lineage and both accumulated within tertiary lymphoid structures, they carried different transcriptional signatures, suggesting they perform different functions within the immune hub. One of these states, designated CD4.T_S02, was more abundant toward the geometric core of the TLS, while its counterpart occupied more peripheral positions. This kind of fine-grained spatial segregation within a single lineage hints at a division of labor inside TLS that mirrors, in miniature, the zoned organization of canonical lymphoid organs such as lymph nodes and the spleen.

To complement the abundance-gradient analysis, the team constructed weighted chemokine networks centered on three key signaling molecules: CXCL13, CXCL12, and the paired chemokines CCL19 and CCL21. Chemokines are the trafficking signals of the immune system, guiding cells to their destinations through gradients and receptor-ligand matching. CXCL13 and CCL19/21 are classically associated with lymphoid organization — they recruit B cells and helper T cells into structured aggregates and help maintain the boundary between distinct lymphoid zones — while CXCL12 has been implicated in both lymphoid organization and immunosuppressive niches. By mapping how these chemokine signals relate to the inferred cell states across space, the researchers could ask whether the transcriptional picture of TLS organization was corroborated by an independent, signaling-centered lens.

It was. The chemokine network analysis revealed two recurrent communities of cell states. The first was a lymphocyte activation community confined to the TLS themselves, consistent with the idea that the core of these structures is where immune cells are being primed and activated. The second was an effector-focused community that extended outward into the surrounding tumor tissue, suggesting that TLS do not merely house immune activity but actively export it — dispatching armed effector cells into the tumor proper, where they can encounter and attack malignant cells. This core-to-periphery functional gradient provides a mechanistic rationale for the clinical association between TLS presence and better outcomes: a tumor with well-organized TLS is not just decorated with immune cells, it is plugged into a production line for antitumor immunity.

One of the most intriguing recurring characters in this spatial drama was a neutrophil cell state of tentative identity that appeared as a hub across all three chemokine axes the researchers examined. Neutrophils are usually cast as short-lived, blunt instruments of innate immunity, and in many tumors they are associated with immunosuppression. The repeated emergence of a neutrophil state at the center of TLS-associated chemokine networks raises the possibility that a specialized neutrophil population may play an architectural or regulatory role within these structures — perhaps helping to organize the recruitment of lymphocytes, or modulating the signals that keep the TLS intact. The authors are careful to label this state’s identity as tentative, and defining it precisely will be a task for future work, but its centrality across independent analyses makes it one of the study’s most provocative leads.

Taken together, the two analytical strategies — the TLS-centric abundance gradient and the weighted chemokine networks — converge on a coherent model. Tertiary lymphoid structures, in this view, are spatially zoned organs: an active core where lymphocyte activation and germinal center-like processes dominate, surrounded by a more diffuse effector periphery where armed immune cells transition into the tumor tissue. The zones are not arbitrary; they are organized through a shared, key set of chemokine signaling pathways, with CXCL13, CXCL12, and CCL19/21 acting as the molecular mortar that holds the architecture in place. This zoned model reframes TLS from static histological features into dynamic, functionally compartmentalized machines for generating and deploying antitumor immunity.

The implications for cancer medicine are considerable. TLS are already the subject of intense interest as biomarkers for immunotherapy response, and numerous clinical efforts aim to induce or mature them in tumors that lack them. The new findings suggest that such efforts should be evaluated not simply by whether TLS appear, but by whether they acquire the correct internal organization — the right cell states in the right places, wired together by the right chemokine signals. A disorganized aggregate of lymphocytes may not function like a properly zoned TLS, and therapies that reshape chemokine signaling could, in principle, convert poorly structured infiltrates into fully functional immune hubs. The cell state atlas generated in this study offers a reference against which such interventions could be measured.

The study, conducted under ethics approvals from the University of Tokyo and Keio University School of Medicine and supported by JSPS KAKENHI grants, also demonstrates the maturing of spatial transcriptomics as a discovery platform. By combining computational state inference with explicit spatial modeling and network analysis, the researchers extracted organizational principles that neither approach alone would have revealed. As the technology spreads and atlases of this kind accumulate across cancer types, the field moves closer to a genuinely spatial understanding of the tumor immune microenvironment — one in which the arrangement of cells, not merely their presence, becomes a target of measurement, prediction, and ultimately therapy. For now, the message of this work is clear: to understand how tumors’ hidden immune organs work, one must look not just at who is there, but at who is where, and at the chemical conversations that put them there.

Subject of Research: Spatial organization and chemokine network architecture of tertiary lymphoid structures in tumors

Article Title: Spatial transcriptomics reveals cell state-level organization and chemokine network architecture within tertiary lymphoid structures

Article References: Yan, A., Iwasawa, T., Tanaka, N., Kakimi, K., Lysenko, A., & Tsunoda, T. (2026). Spatial transcriptomics reveals cell state-level organization and chemokine network architecture within tertiary lymphoid structures. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04529-2

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04529-2

Keywords: tertiary lymphoid structures, spatial transcriptomics, chemokine signaling networks, cell states, tumor microenvironment, cancer immunology, CXCL13, CXCL12, CCL19, CD4 T cells, neutrophils, immunotherapy biomarkers

Tertiary lymphoid structures are organized aggregates of immune cells that form outside the conventional lymph nodes and spleen. In many solid tumors, they are viewed as encouraging signs: evidence that the immune system has mounted a localized, sustained response against the malignancy. These structures typically contain T cells and B cells arranged in patterns that resemble miniature lymphoid organs, sometimes even developing the germinal centers where antibodies are refined. In cancers such as melanoma, lung cancer, and breast cancer, the presence and density of TLS have repeatedly been linked to better responses to immunotherapy and improved survival. The brain, however, has long been considered an immunologically quiet environment, protected by the blood-brain barrier and populated by its own specialized immune cells, so the role of TLS in brain tumors has remained far less clear.

That gap is precisely what a team of neurosurgeons and researchers affiliated with Kunming Medical University and collaborating institutions in China set out to address. In a retrospective study published in the journal Cancer Immunology, Immunotherapy, the investigators analyzed tissue samples from 62 patients with isocitrate dehydrogenase, or IDH, wildtype glioblastoma who were treated at their institution between 2016 and 2023. IDH wildtype status defines the most aggressive and common form of glioblastoma in adults, and it is the subtype for which new prognostic tools are most urgently needed. The study was conducted in accordance with the Declaration of Helsinki, with ethics approval from the First Affiliated Hospital of Kunming Medical University and written informed consent obtained from all participants or their legal representatives.

The methodological heart of the study lies in how the researchers detected and classified these immune structures. Using standard hematoxylin and eosin staining alongside immunohistochemical staining for CD3, a marker of T cells, and CD20, a marker of B cells, the team identified TLS within resected tumor specimens. Rather than simply recording whether TLS were present or absent, the investigators went a step further and built a grading system that captured two dimensions: the quantity of the structures and their spatial distribution within the tumor region. This distinction matters because a TLS sitting in the peritumoral zone, the tissue surrounding the tumor, may reflect a different immunological situation than one embedded deep within the tumor mass itself, where it would be in direct contact with malignant cells.

The results were striking. TLS were present in 58.1 percent of the cohort, meaning that more than half of these patients carried organized immune structures in or around their tumors. When the researchers correlated TLS status with overall survival using Kaplan-Meier curves, they found that TLS presence, TLS grading, and the extent of surgical resection all showed statistically significant associations with survival outcomes, each reaching the threshold of P less than 0.05. The grading system proved particularly informative. Patients with higher TLS grades, and especially those whose structures were located within the tumor itself, corresponding to the highest category, Score 3, experienced significantly prolonged overall survival compared with patients lacking these structures or harboring only peritumoral ones.

To ensure that this association was not simply a statistical artifact driven by other clinical variables, the team turned to multivariate Cox regression analysis, a standard statistical technique that evaluates the independent contribution of each factor while controlling for the others. The analysis confirmed that TLS grading stood as an independent favorable prognostic factor for overall survival in this glioblastoma cohort. In practical terms, this means that even after accounting for variables such as the extent of resection, the grade of the TLS carried its own predictive weight. The extent of resection, which distinguishes total, subtotal, and partial removal of the tumor, also remained significantly correlated with survival, consistent with decades of neurosurgical evidence, but the TLS signal held its ground alongside it.

The implications of these findings extend beyond prognosis into the realm of treatment selection. Glioblastoma has been a notoriously poor responder to immune checkpoint inhibitors, the class of drugs that has revolutionized the treatment of many other cancers. One leading explanation is that the brain tumor microenvironment lacks the pre-existing immune infrastructure that such therapies require to work. TLS could represent exactly that infrastructure: a localized factory for generating and deploying tumor-specific immune cells. If patients whose tumors contain high-grade, intratumoral TLS are the ones with an already-primed immune response, they may be the subset most likely to benefit from intensified immunotherapeutic interventions, while patients without TLS might need strategies that first induce lymphoid neogenesis before checkpoint blockade could have any chance of success.

The authors are appropriately measured in their claims. They emphasize that the proposed TLS grading system provides a potential prognostic stratification tool for glioblastoma that warrants external validation, a crucial caveat in a field where promising single-institution findings sometimes fail to replicate in larger, independent cohorts. With 62 patients, the study is a meaningful proof of concept but not a definitive clinical standard. Standardizing how TLS are identified and scored across pathology laboratories, and testing the grading system in independent datasets from other centers, will be essential steps before it could inform treatment decisions at the bedside. The retrospective design also means that the findings demonstrate association rather than causation, and it remains possible that TLS are a marker of some other underlying biological difference rather than an active driver of better outcomes.

Even with those caveats, the study adds an important piece to the evolving picture of glioblastoma immunology. The tumor microenvironment, once viewed as a hostile wasteland for immune activity, is increasingly understood as a complex ecosystem where organized immune structures can and do form. The fact that the location of these structures, not just their number, carries prognostic weight suggests that the spatial architecture of the anti-tumor immune response matters, a principle that resonates with broader trends in cancer immunology where spatial biology is reshaping how tumors are classified. For a disease in which median survival has barely moved in decades, any new, independently validated prognostic factor is significant, and one that could also guide immunotherapy selection would be doubly valuable.

The research, published as an open-access article, was supported by funding from Kunming Medical University, the Health Commission of Yunnan Province, and related regional research programs. The authors reported no relevant financial or non-financial conflicts of interest. As the field moves forward, the challenge will be to translate this grading system from the research laboratory into routine pathology workflows, where hematoxylin and eosin slides and CD3 and CD20 stains are already standard tools. If external validation confirms what this cohort suggests, neuro-oncologists may one day look at a glioblastoma specimen not only for the features that define its malignancy, but for the quiet architecture of the immune response unfolding within it, and use that architecture to decide which patients need the most aggressive immunological reinforcements available.

Subject of Research: Tertiary lymphoid structures as prognostic biomarkers in IDH-wildtype glioblastoma

Article Title: Tertiary lymphoid structures (TLS) classification: a new perspective on glioblastoma patient’s prognosis

Article References: Meng, M., Li, Y., Dai, X., Yang, G., Li, Z., & Tang, Z. (2026). Tertiary lymphoid structures (TLS) classification: a new perspective on glioblastoma patient’s prognosis. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04537-2

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04537-2

Keywords: glioblastoma, tertiary lymphoid structures, tumor microenvironment, prognostic markers, immunotherapy, IDH-wildtype, immunohistochemistry, overall survival, neuro-oncology, Cox regression, CD3, CD20